Search Legislation

Advanced Search

Council Regulation (EEC) No 2377/90 (repealed)Show full title

Council Regulation (EEC) No 2377/90 of 26 June 1990 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (repealed)

Help about what version

What Version

Help about advanced features

Advanced Features

More Resources

Revised version PDFs

Help about UK-EU Regulation

Legislation originating from the EU

When the UK left the EU, legislation.gov.uk published EU legislation that had been published by the EU up to IP completion day (31 December 2020 11.00 p.m.). On legislation.gov.uk, these items of legislation are kept up-to-date with any amendments made by the UK since then.

Close

This item of legislation originated from the EU

Legislation.gov.uk publishes the UK version. EUR-Lex publishes the EU version. The EU Exit Web Archive holds a snapshot of EUR-Lex’s version from IP completion day (31 December 2020 11.00 p.m.).

Status:

Point in time view as at 20/01/2008.

Changes to legislation:

There are currently no known outstanding effects for the Council Regulation (EEC) No 2377/90 (repealed), Division 1. . Help about Changes to Legislation

Close

Changes to Legislation

Revised legislation carried on this site may not be fully up to date. At the current time any known changes or effects made by subsequent legislation have been applied to the text of the legislation you are viewing by the editorial team. Please see ‘Frequently Asked Questions’ for details regarding the timescales for which new effects are identified and recorded on this site.

[F11. Anti-infectious agents U.K.

1.1. Chemotheurapeutics U.K.

1.1.1. Sulfonamides U.K.
Pharmacologically active substance(s) Marker residue Animal species MRLs Target tissues Other provisions
All substances belonging to the sulfonamide group Parent drug All food-producing species 100 μg/kg Muscle The combined total residues of all substances within the sulfonamide group should not exceed 100 μg/kg
100 μg/kg Fat
100 μg/kg Liver
100 μg/kg Kidney
Bovine, ovine, caprine 100 μg/kg Milk
1.1.2. Diamino pyrimidine derivatives U.K.
a

[F2For porcine and poultry species this MRL relates to ‘ skin and fat in natural proportions ’ .

b

For fin fish this MRL relates to ‘ muscle and skin in natural proportions ’ .]

Pharmacologically active substance(s) Marker residue Animal species MRLs Target tissues Other provisions
Baquiloprim Baquiloprim Bovine 10 μg/kg Fat
300 μg/kg Liver
150 μg/kg Kidney
30 μg/kg Milk
Porcine 40 μg/kg Skin and fat
50 μg/kg Liver
50 μg/kg Kidney
[F3Trimethoprim Trimethoprim All food producing species except equidae 50 μg/kg Fat a Not for use in animals from which eggs are produced for human consumption
50 μg/kg Muscle  b
50 μg/kg Liver
50 μg/kg Kidney
50 μg/kg Milk
Equidae 100 μg/kg Muscle
100 μg/kg Fat
100 μg/kg Liver
100 μg/kg Kidney]

Textual Amendments

1.2. Antibiotics U.K.

1.2.1. Penicillins U.K.
a

[F4For intramammary use only.

b

[F5Not for use in animals from which eggs are produced for human consumption.] ]

Pharmacologically active substance(s) Marker residue Animal species MRLs Target tissues Other provisions
Amoxicyllin Amoxicyllin All food-producing species 50 μg/kg Muscle
50 μg/kg Fat
50 μg/kg Liver
50 μg/kg Kidney
4 μg/kg Milk
Ampicillin Ampicillin All food-producing species 50 μg/kg Muscle
50 μg/kg Fat
50 μg/kg Liver
50 μg/kg Kidney
4 μg/kg Milk
Benzylpenicillin Benzylpenicillin All food-producing species 50 μg/kg Muscle
50 μg/kg Fat
50 μg/kg Liver
50 μg/kg Kidney
4 μg/kg Milk
Cloxacillin Cloxacillin All food-producing species 300 μg/kg Muscle
300 μg/kg Fat
300 μg/kg Liver
300 μg/kg Kidney
30 μg/kg Milk
Dicloxacillin Dicloxacillin All food-producing species 300 μg/kg Muscle
300 μg/kg Fat
300 μg/kg Liver
300 μg/kg Kidney
30 μg/kg Milk
[F6Nafcillin Nafcillin All ruminants a 300 μg/kg Muscle
300 μg/kg Fat
300 μg/kg Liver
300 μg/kg Kidney
30 μg/kg Milk]
Oxacillin Oxacillin All food-producing species 300 μg/kg Muscle
300 μg/kg Fat
300 μg/kg Liver
300 μg/kg Kidney
30 μg/kg Milk
Penethamate Benzylpenicillin Bovine 50 μg/kg Muscle
50 μg/kg Fat
50 μg/kg Liver
50 μg/kg Kidney
4 μg/kg Milk
[F7 Porcine 50 μg/kg Muscle
50 μg/kg Fat
50 μg/kg Liver
50 μg/kg Kidney ]
[F8 All mammalian-food producing species 50 μg/kg Muscle
50 μg/kg Fat
50 μg/kg Liver
50 μg/kg Kidney
4 μg/kg Milk ]
[F9Phenoxymethylpenicillin Phenoxymethylpenicillin Porcine 25 μg/kg Muscle
25 μg/kg Liver
25 μg/kg Kidney
[F5Poultry b 25  μg/kg Muscle
25  μg/kg Skin + fat
25  μg/kg Liver
25  μg/kg Kidney ] ]

Textual Amendments

1.2.2. Cephalosporins U.K.
a

[F10For porcine species this MRL relates to ‘ skin and fat in natural proportions ’ .]

Pharmacologically active substance(s) Marker residue Animal species MRLs Target tissues Other provisions
[F11Cefacetrile Cefacetrile Bovine 125 μg/kg Milk For intramammary use only]
[F12Cefalexin Cefalexin Bovine 200 μg/kg Muscle
200 μg/kg Fat
200 μg/kg Liver
1 000  μg/kg Kidney
100 μg/kg Milk ]
[F13Cefalonium Cefalonium Bovine 20 μg/kg Milk ]
[F14Cefapirin Sum of cephapirin and desacetylcephapirin Bovine 50 μg/kg Muscle
50 μg/kg Fat
100 μg/kg Kidney
60 μg/kg Milk ]
Cefazolin Cefazolin Bovine, ovine, caprine 50 μg/kg Milk
[F15Cefoperazone Cefoperazone Bovine 50 μg/kg Milk ]
Cefquinome Cefquinome Bovine 50 μg/kg Muscle
50 μg/kg Fat
100 μg/kg Liver
200 μg/kg Kidney
20 μg/kg Milk
[F16 Porcine 50 μg/kg Muscle
50 μg/kg Skin + fat
100 μg/kg Liver
200 μg/kg Kidney ]
[F17 Equidae 50 μg/kg Muscle
50 μg/kg Fat
100 μg/kg Liver
200 μg/kg Kidney ]
[F18Ceftiofur Sum of all residues retaining the betalactam structure expressed as desfuroylceftiofur All mammalian food-producing species 1 000  μg/kg Muscle
2 000  μg/kg Fat a
2 000  μg/kg Liver
6 000  μg/kg Kidney
100  μg/kg Milk]

Textual Amendments

1.2.3. Quinolones U.K.
a

[F2For fin fish this MRL relates to ‘ muscle and skin in natural proportions ’ .

b

For porcine species this MRL relates to ‘ skin and fat in natural proportions ’ .

c

[F19Not for use in animals from which milk or eggs are produced for human consumption; MRLs for fat, liver and kidney do not apply to fin fish.

d

For porcine and poultry species this MRL relates to ‘ skin and fat in natural proportions ’ .] ]

Pharmacologically active substance(s) Marker residue Animal species MRLs Target tissues Other provisions
[F3Danofloxacin Danofloxacin [X1All food producing species except bovine, ovine, caprine, porcine and poultry] 100 μg/kg Muscle b
50 μg/kg Fat a
200 μg/kg Liver
200 μg/kg Kidney
Bovine, ovine, caprine 200 μg/kg Muscle
100 μg/kg Fat
400 μg/kg Liver
400 μg/kg Kidney
30 μg/kg Milk
Poultry 200 μg/kg Muscle Not for use in animals from which eggs are produced for human consumption
100 μg/kg Skin and fat
400 μg/kg Liver
400 μg/kg Kidney
Difloxacin Difloxacin All food producing species except bovine, ovine, caprine and poultry 300 μg/kg Muscle b
100 μg/kg Fat
800 μg/kg Liver
600 μg/kg Kidney
Bovine, ovine, caprine 400 μg/kg Muscle Not for use in animals from which milk is produced for human consumption
100 μg/kg Fat
1 400  μg/kg Liver
800 μg/kg Kidney
Porcine 400 μg/kg Muscle
100 μg/kg Skin and fat
800 μg/kg Liver
800 μg/kg Kidney
Poultry 300 μg/kg Muscle Not for use in animals from which eggs are produced for human consumption
400 μg/kg Skin and fat
1 900  μg/kg Liver
600 μg/kg Kidney
Enrofloxacin Sum of enrofloxacin and ciprofloxacin All food producing species except bovine, ovine, caprine, porcine, rabbits and poultry 100 μg/kg Muscle b
100 μg/kg Fat
200 μg/kg Liver
200 μg/kg Kidney
Bovine, ovine, caprine 100 μg/kg Muscle
100 μg/kg Fat
300 μg/kg Liver
200 μg/kg Kidney
100 μg/kg Milk
Porcine, rabbits 100 μg/kg Muscle
100 μg/kg Fat a
200 μg/kg Liver
300 μg/kg Kidney
Poultry 100 μg/kg Muscle Not for use in animals from which eggs are produced for human consumption
100 μg/kg Skin and fat
200 μg/kg Liver
300 μg/kg Kidney
Flumequine Flumequine All food producing species except bovine, ovine, caprine, porcine, poultry and fin fish 200 μg/kg Muscle
250 μg/kg Fat
500 μg/kg Liver
1 000  μg/kg Kidney
Bovine, porcine, ovine, caprine 200 μg/kg Muscle
300 μg/kg Fat a
500 μg/kg Liver
1 500  μg/kg Kidney
50 μg/kg Milk
Poultry 400 μg/kg Muscle Not for use in animals from which eggs are produced for human consumption
250 μg/kg Skin and fat
800 μg/kg Liver
1 000  μg/kg Kidney
Fin fish 600 μg/kg Muscle and skin in natural proportion ]
[F20Marbofloxacin Marbofloxacin Bovine 150 μg/kg Muscle
50 μg/kg Fat
150 μg/kg Liver
150 μg/kg Kidney
75 μg/kg Milk
Porcine 150 μg/kg Muscle
50 μg/kg Skin and fat
150 μg/kg Liver
150 μg/kg Kidney ]
[F21Oxolinic acid Oxolinic acid Porcine 100 μg/kg Muscle
50 μg/kg Skin and fat
150 μg/kg Liver
150 μg/kg Kidney
Chicken 100 μg/kg Muscle Not for use in animals from which eggs are produced for human consumption
50 μg/kg Skin and fat
150 μg/kg Liver
150 μg/kg Kidney
Fin fish 100 μg/kg Muscle and skin in natural proportions
[F19All food-producing species c 100 μg/kg Muscle a
50 μg/kg Fat d
150 μg/kg Liver
150 μg/kg Kidney ] ]
Sarafloxacin Sarafloxacin Chicken 10 μg/kg Skin and fat
100 μg/kg Liver
Salmonidae 30 μg/kg Muscle and skin in natural proportions

Editorial Information

Textual Amendments

1.2.4. Macrolides U.K.
a

[F2For fin fish this MRL relates to a ‘ muscle and skin in natural proportions ’ .

b

For porcine species this MRL relates to ‘ skin and fat in natural proportions ’ .

c

For porcine and poultry species this MRL relates to ‘ skin and fat in natural proportions ’ .

d

[F22 [X2Not for use in animals from which milk is produced for human consumption.] ]

e

[F23Not for use in animals from which milk is produced for human consumption.]

f

[F24Not for use in animals from which eggs are produced for human consumption.

g

For poultry species, this MRL relates to “ skin and fat in natural proportions ” .] ]

Pharmacologically active substance(s) Marker residue Animal species MRLs Target tissues Other provisions
[ F25. . . . .]
[F3Erythromycin Erythromicyin A All food producing species 200 μg/kg Muscle  a
200 μg/kg Fat  b
200 μg/kg Liver
200 μg/kg Kidney
40 μg/kg Milk
150 μg/kg Eggs ]
Spiramycin Sum of spiramycin and neospiramycin Bovine 200 μg/kg Muscle
300 μg/kg Fat
300 μg/kg Liver
300 μg/kg Kidney
200 μg/kg Milk
Chicken 200 μg/kg Muscle
300 μg/kg Skin and fat
400 μg/kg Liver
[F26 Spiramycin 1 Porcine 250 μg/kg Muscle
2 000  μg/kg Liver
1 000  μg/kg Kidney ]
[F3Tilmicosin Tilmicosin All food producing species except poultry 50 μg/kg Muscle  a
50 μg/kg Fat  b
1 000  μg/kg Liver
1 000  μg/kg Kidney
50 μg/kg Milk
Poultry 75 μg/kg Muscle Not for use in animals from which eggs are produced for human consumption
75 μg/kg Sin and fat
1 000  μg/kg Liver
250 μg/kg Kidney
[F22 [X2Tulathromycin (2R,3S,4R,5R,8R,10R,11R,12S, 13S,14R)-2-ethyl-3,4,10,13-tetrahydroxy-3,5,8,10,12,14-hexamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)-ß-D-xylo-hexopy-ranosyl]oxy]-1-oxa-6-azacyclopent-decan-15-one expressed as tulathromycin equivalents Bovine d 100  μg/kg Fat
3 000  μg/kg Liver
3 000  μg/kg Kidney
Porcine 100  μg/kg Skin + fat
3 000  μg/kg Liver
3 000  μg/kg Kidney ] ]
Tylosin Tylosin A All food producing species 100 μg/kg Fat  c
100 μg/kg Muscle  a
100 μg/kg Liver
100 μg/kg Kidney
50 μg/kg Milk
200 μg/kg Eggs ]
[F24Tylvalosin Sum of tylvalosin and 3-O-acetyltylosin Porcine 50 μg/kg Muscle
50 μg/kg Fat b
50 μg/kg Liver
50 μg/kg Kidney
Poultry f 50 μg/kg Fat g
50 μg/kg Liver ]

Editorial Information

Textual Amendments

[F271.2.5. Florfenicol and related compounds U.K.
a

Not for use in animals from which eggs are produced for human consumption, MRLs for fat, liver and kidney do not apply to fin fish.

b

For fin fish muscle relates to ‘ muscle and skin in natural proportions ’ .

c

For porcine and poultry species this MRL relates to ‘ skin and fat in natural proportions ’ .]

Pharmacologically active Substance(s) Marker residue Animal species MRLs Target tissues
Thiamphenicol Thiamphenicol All food producing species a 50 μg/kg Muscle b
50 μg/kg Fat c
50 μg/kg Liver
50 μg/kg Kidney
50 μg/kg Milk

Textual Amendments

1.2.6. Tetracyclines U.K.
Pharmacologically active substance(s) Marker residue Animal species MRLs Target tissues Other provisions
Chlortetracycline Sum of parent drug and its 4- epimer All food-producing species 100 μg/kg Muscle
300 μg/kg Liver
600 μg/kg Kidney
100 μg/kg Milk
200 μg/kg Eggs
Doxycycline Doxycycline Bovine 100 μg/kg Muscle
Not for use in animals from which milk is produced for human consumption 300 μg/kg Liver
600 μg/kg Kidney
Porcine 100 μg/kg Muscle
300 μg/kg Skin and fat
300 μg/kg Liver
600 μg/kg Kidney
Poultry 100 μg/kg Muscle
Not for use in animals from which eggs are produced for human consumption 300 μg/kg Skin and fat
300 μg/kg Liver
600 μg/kg Kidney
Oxytetracycline Sum of parent drug and its 4-epimer All food-producing species 100 μg/kg Muscle
300 μg/kg Liver
600 μg/kg Kidney
100 μg/kg Milk
200 μg/kg Eggs
Tetracycline Sum of parent drug and its 4-epimer All food-producing species 100 μg/kg Muscle
300 μg/kg Liver
600 μg/kg Kidney
100 μg/kg Milk
200 μg/kg Eggs
1.2.7. Naphtalene-ringed ansamycin U.K.
Pharmacologically active substance(s) Marker residue Animal species MRLs Target tissues Other provisions
Rifaximin Rifaximin Bovine 60 μg/kg Milk
1.2.8. Pleuromutilines U.K.
Pharmacologically active substance(s) Marker residue Animal species MRLs Target tissues Other provisions
[F12Tiamulin Sum of metabolites that may be hydrolysed to 8-a-hydroxymutilin Porcine 100 μg/kg Muscle
500 μg/kg Liver
Chicken 100 μg/kg Muscle
100 μg/kg Skin and fat
1 000  μg/kg Liver
[F20Rabbits 100 μg/kg Muscle
500 μg/kg Liver ]
[F15Turkey 100 μg/kg Muscle
100 μg/kg Skin and fat
300 μg/kg Liver ]
Tiamulin 1 000  μg/kg Eggs ]
Valnemulin Valnemulin Porcine 50 μg/kg Muscle
500 μg/kg Liver
100 μg/kg Kidney
[F281.2.9. Lincosamides U.K.
a

[F2For porcine and poultry species this MRL relates to ‘ skin and fat in natural proportions ’ .

b

For fin fish this MRL relates to ‘ muscle and skin in natural proportions ’ .] ]

Pharmacologically active substance(s) Marker residue Animal species MRLs Target tissues Other provisions
[F3Lincomycin Lincomicyn All food producing species 50 μg/kg Fat  a
100 μg/kg Muscle  b
500 μg/kg Liver
1 500  μg/kg Kidney
150 μg/kg Milk
50 μg/kg Eggs ]
[F20Pirlimycin Pirlimycin Bovine 100 μg/kg Muscle
100 μg/kg Fat
1 000  μg/kg Liver
400 μg/kg Kidney
100 μg/kg Milk
Porcine 100 μg/kg Muscle
50 μg/kg Skin and fat
500 μg/kg Liver
1 500  μg/kg Kidney
Chicken 100 μg/kg Muscle
50 μg/kg Skin and fat
500 μg/kg Liver
1 500  μg/kg Kidney
50 μg/kg Eggs ]

Textual Amendments

[F161.2.10. Aminoglycosides U.K.
a

[F2For porcine and poultry species this MRL relates to ‘ skin and fat in natural proportions ’ .

b

For fin fish this MRL relates to ‘ muscle and skin in natural proportions ’ .

c

[F29Not for use in animals from which eggs are produced for human consumption.] ] ]

Pharmacologically active substance(s) Marker residue Animal species MRLs Target tissues Other provisions
Apramycin Apramycin Bovine 1 000  μg/kg Muscle Not for use in animals from which milk is produced for human consumption
1 000  μg/kg Fat
10 000  μg/kg Liver
20 000  μg/kg Kidney
[F30Dihydrostreptomycin Dihydrostreptomycin All ruminants 500 μg/kg Muscle
500 μg/kg Fat
500 μg/kg Liver
1 000 μg/kg Kidney
200 μg/kg Milk
Porcine 500 μg/kg Muscle
500 μg/kg Skin + fat
500 μg/kg Liver
1 000 μg/kg Kidney
Rabbits 500 μg/kg Muscle
500 μg/kg Fat
500 μg/kg Liver
1 000 μg/kg Kidney ]
[F31Gentamicin Sum of gentamicin C1, gentamicin C1a, gentamicin C2 and gentamicin C2a Bovine 50 μg/kg Muscle
50 μg/kg Fat
200 μg/kg Liver
750 μg/kg Kidney
100 μg/kg Milk
Porcine 50 μg/kg Muscle
50 μg/kg Skin and fat
200 μg/kg Liver
750 μg/kg Kidney ]
[F29Kanamycin Kanamycin A All food producing species except fish c 100 μg/kg Muscle
100 μg/kg Fat a
600 μg/kg Liver
2 500  μg/kg Kidney
150 μg/kg Milk ]
[F2Neomycin (including framycetin) Neomycin B All food producing species 500 μg/kg Fat  a
500 μg/kg Muscle  b
500 μg/kg Liver
5 000  μg/kg Kidney
1 500  μg/kg Milk
500 μg/kg Eggs ]
[F3Paromomycin Paromomycin All food producing species 500 μg/kg Muscle b Not for use in animals from which milk or eggs are produced for human consumption
1 500  μg/kg Liver
1 500  μg/kg Kidney
Spectinomycin Spectinomycin All food producing species except ovine 500 μg/kg Fat a Not for use in animals from which eggs are produced for human consumption
300 μg/kg Muscle  b
1 000  μg/kg Liver
5 000  μg/kg Kidney
200 μg/kg Milk
Ovine 300 μg/kg Muscle
500 μg/kg Fat
2 000  μg/kg Liver
5 000  μg/kg Kidney
200 μg/kg Milk]
[F30Streptomycin Streptomycin All ruminants 500 μg/kg Muscle
500 μg/kg Fat
500 μg/kg Liver
1 000 μg/kg Kidney
200 μg/kg Milk
Porcine 500 μg/kg Muscle
500 μg/kg Skin + fat
500 μg/kg Liver
1 000 μg/kg Kidney
Rabbits 500 μg/kg Muscle
500 μg/kg Fat
500 μg/kg Liver
1 000 μg/kg Kidney ]

Textual Amendments

[F261.2.11. Other antibiotics U.K.
Pharmacologically active substance(s) Marker residue Animal species MRLs Target tissues Other provisions
Novobiocin Novobiocin Bovine 50 μg/kg Milk ]
[F321.2.12. Polypeptides U.K.
Pharmacologically active substance(s) Marker residue Animal species MRLs Target tissues Other provisions
Bacitracin Sum of bacitracin A, bacitracin B, and bacitracin C Bovine 100 μg/kg Milk
[F33 Rabbits 150 μg/kg Muscle
150 μg/kg Fat
150 μg/kg Liver
150 μg/kg Kidney ] ]

Textual Amendments

Textual Amendments

[F141.2.13. Beta-lactamase inhibitors U.K.
Pharmacologically active substance(s) Marker residue Animal species MRLs Target tissues Other provisions
Clavulanic acid Clavulanic acid Bovine 100 μg/kg Muscle
100 μg/kg Fat
200 μg/kg Liver
400 μg/kg Kidney
200 μg/kg Milk
Porcine 100 μg/kg Muscle
100 μg/kg Skin and fat
200 μg/kg Liver
400 μg/kg Kidney ]
[F21.2.14. Polymyxins U.K.
a

For porcine and poultry species this MRL relates to ‘ skin and fat in natural proportions ’ .

b

For fin fish this MRL relates to ‘ muscle and skin in natural proportions ’ .]

Pharmacologically active substance Marker residue Animal species MRLs Target tissues Other provisions
Colistin Colistin All food producing species 150 μg/kg Fat  a
150 μg/kg Muscle  b
150 μg/kg Liver
200 μg/kg Kidney
50 μg/kg Milk
300 μg/kg Eggs
[F341.2.15. Orthosomycins U.K.
a

For porcine and poultry species, this MRL relates to skin and fat in natural proportions.

b

Not for use in animals from which eggs are produced for human consumption.]

Pharmacologically active substance(s) Marker residue Animal species MRLs Target tissues Other provisions
Avilamycin Dichloroisoeverninic acid Porcine 50 μg/kg Muscle
100 μg/kg Fat a
300 μg/kg Liver
200 μg/kg Kidney
Rabbit 50 μg/kg Muscle
100 μg/kg Fat
300 μg/kg Liver
200 μg/kg Kidney
Poultry b 50 μg/kg Muscle
100 μg/kg Fat a
300 μg/kg Liver
200 μg/kg Kidney

Textual Amendments

[F241.2.16. Ionophores U.K.
a

For poultry species, this MRL relates to ‘ skin and fat in natural proportions ’ .] ]

Pharmacologically active substance(s) Marker residue Animal species MRLs Target tissues Other provisions
Monensin Monensin A Bovine 2 μg/kg Muscle
10 μg/kg Fat
30 μg/kg Liver
2 μg/kg Kidney
2 μg/kg Milk
Lasalocid Lasalocid A Poultry 20 μg/kg Muscle
100 μg/kg Fat a
100 μg/kg Liver
50 μg/kg Kidney
150 μg/kg Eggs

Textual Amendments

Back to top

Options/Help

Print Options

Close

Legislation is available in different versions:

Latest Available (revised):The latest available updated version of the legislation incorporating changes made by subsequent legislation and applied by our editorial team. Changes we have not yet applied to the text, can be found in the ‘Changes to Legislation’ area.

Original (As adopted by EU): The original version of the legislation as it stood when it was first adopted in the EU. No changes have been applied to the text.

Point in Time: This becomes available after navigating to view revised legislation as it stood at a certain point in time via Advanced Features > Show Timeline of Changes or via a point in time advanced search.

Close

See additional information alongside the content

Geographical Extent: Indicates the geographical area that this provision applies to. For further information see ‘Frequently Asked Questions’.

Show Timeline of Changes: See how this legislation has or could change over time. Turning this feature on will show extra navigation options to go to these specific points in time. Return to the latest available version by using the controls above in the What Version box.

Close

Opening Options

Different options to open legislation in order to view more content on screen at once

Close

More Resources

Access essential accompanying documents and information for this legislation item from this tab. Dependent on the legislation item being viewed this may include:

  • the original print PDF of the as adopted version that was used for the EU Official Journal
  • lists of changes made by and/or affecting this legislation item
  • all formats of all associated documents
  • correction slips
  • links to related legislation and further information resources
Close

Timeline of Changes

This timeline shows the different versions taken from EUR-Lex before exit day and during the implementation period as well as any subsequent versions created after the implementation period as a result of changes made by UK legislation.

The dates for the EU versions are taken from the document dates on EUR-Lex and may not always coincide with when the changes came into force for the document.

For any versions created after the implementation period as a result of changes made by UK legislation the date will coincide with the earliest date on which the change (e.g an insertion, a repeal or a substitution) that was applied came into force. For further information see our guide to revised legislation on Understanding Legislation.

Close

More Resources

Use this menu to access essential accompanying documents and information for this legislation item. Dependent on the legislation item being viewed this may include:

  • the original print PDF of the as adopted version that was used for the print copy
  • correction slips

Click 'View More' or select 'More Resources' tab for additional information including:

  • lists of changes made by and/or affecting this legislation item
  • confers power and blanket amendment details
  • all formats of all associated documents
  • links to related legislation and further information resources